Related Experiment Video
Updated: Jul 3, 2026
Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Blocking CK2α-Bclaf1 Preserves Oligodendrocytes After Neonatal Hypoxic Injury
Chien-Fang Huang1, Ti-Jie Yuan1, Ming-Yi Lin1
1Department of Biotechnology and Bioindustry Sciences, National Cheng Kung University, Tainan, Taiwan.
Insights
Neonatal hypoxic injury kills oligodendrocytes (OLs) by activating CK2α-Bclaf1. Therapies targeting this pathway may protect developing brains and prevent cognitive deficits.
Area of Science:
- Neuroscience
- Developmental Biology
- Cellular Pathology
Background:
- Neonatal hypoxic injury impairs white matter development in preterm infants, causing long-term cognitive and mental deficits.
- Prolonged hypoxia leads to oligodendrocyte (OL) death and delayed myelination, even after oxygen levels normalize.
Purpose of the Study:
- To investigate the roles of serine/threonine kinase CK2α and transcription factor Bclaf1 in OL survival during hypoxia.
- To identify potential therapeutic targets for mitigating hypoxia-induced OL damage in newborns.
Main Methods:
- Examined the interaction between CK2α and Bclaf1 under hypoxic conditions.
- Assessed the impact of Vhl (hypoxia-inducible E3 ligase) on OL apoptosis.
- Evaluated the protective effects of CK2 inhibitor silmitasertib and curcumin on OLs in a neonatal hypoxic injury model.
Main Results:
- CK2α-mediated phosphorylation of Bclaf1 promotes hypoxia-induced OL apoptosis.
- Restoring Vhl expression reversed hypoxia-mediated OL death.
- Silmitasertib and curcumin treatment protected OLs and preserved pre-myelinating capacity after hypoxic injury.
Conclusions:
- CK2α and Bclaf1 are key regulators of OL apoptosis in neonatal hypoxic injury.
- Targeting the CK2α-Bclaf1 pathway offers a potential therapeutic strategy for neonatal hypoxic brain injury.
- Silmitasertib and curcumin show promise in protecting developing white matter from hypoxic damage.
Abstract:
Neonatal hypoxic injury is a common disorder that disrupts white matter development in preterm newborns, with long-term impacts on cognitive and mental function. While oxygen availability controls oligodendrocyte (OL) differentiation, prolonged hypoxia leads to OL death and impairs subsequent myelination even after returning to normoxic conditions. In this study, we uncovered the detrimental roles of the serine/threonine kinase CK2α and the transcriptional factor Bclaf1 in OL survival under hypoxic conditions. Phosphorylated Bclaf1 by CK2α drives hypoxia-mediated OL apoptosis, which can be reversed by introducing the hypoxia-inducible E3 ligase Vhl. Additionally, acute treatment with the clinically approved CK2 inhibitor silmitasertib and the herbal supplement curcumin not only reduces CK2α-Bclaf1 activity but also protects OLs and restores pre-myelinating ability in newborns following hypoxic injury. This approach unveils a key molecular regulation in hypoxia-related OL pathology and highlights a potential therapeutic strategy to mitigate neonatal hypoxic injury and prevent mental health complications.
